P = NS) (Figure 7D)
Different types of protein provide different benefits, said Corbion's Beech
The blend totals 2 billion AFU and contains: Akkermansia muciniphila Clostridium butyricum Clostridium beijerinckii Anaerobutyricum hallii Bifidobacterium infantis It also includes chicory inulin and oligofructose, prebiotics that act as "food" for probiotics
In effect, a portion of consumer spending once allocated to food is now being redirected toward pharmaceuticals
Research shows that peptides like semaglutide cannot pass through the skin in enough amounts to work
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
